Fresenius SE & Co. KGaA (OTCMKTS:FSNUY - Get Free Report) announced a dividend on Thursday, May 22nd, investing.com reports. Stockholders of record on Wednesday, May 28th will be given a dividend of 0.1827 per share on Wednesday, June 4th. This represents a dividend yield of 1.48%. The ex-dividend date is Tuesday, May 27th. This is a 9.3% increase from Fresenius SE & Co. KGaA's previous dividend of $0.17.
Fresenius SE & Co. KGaA Price Performance
Shares of FSNUY traded up $0.16 during mid-day trading on Tuesday, reaching $12.51. The company had a trading volume of 35,702 shares, compared to its average volume of 59,084. The company's 50 day simple moving average is $11.34 and its 200 day simple moving average is $10.09. Fresenius SE & Co. KGaA has a 1-year low of $7.43 and a 1-year high of $12.62. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.05 and a current ratio of 1.36. The company has a market capitalization of $27.94 billion, a price-to-earnings ratio of 65.83 and a beta of 0.78.
Fresenius SE & Co. KGaA (OTCMKTS:FSNUY - Get Free Report) last posted its quarterly earnings results on Wednesday, May 7th. The company reported $0.23 earnings per share for the quarter, beating analysts' consensus estimates of $0.22 by $0.01. The company had revenue of $5.92 billion during the quarter, compared to analyst estimates of $5.41 billion. Analysts expect that Fresenius SE & Co. KGaA will post 0.79 EPS for the current year.
Analyst Ratings Changes
Several research firms recently commented on FSNUY. Deutsche Bank Aktiengesellschaft reiterated a "buy" rating on shares of Fresenius SE & Co. KGaA in a research report on Monday, February 3rd. Morgan Stanley reiterated an "overweight" rating on shares of Fresenius SE & Co. KGaA in a research report on Thursday, May 15th.
Get Our Latest Research Report on FSNUY
About Fresenius SE & Co. KGaA
(
Get Free Report)
Fresenius SE & Co KGaA, a health care company, provides products and services for chronically ill patients. It operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure.
Further Reading
Before you consider Fresenius SE & Co. KGaA, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Fresenius SE & Co. KGaA wasn't on the list.
While Fresenius SE & Co. KGaA currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
